|
|
Article: Denosumab increased BMD in 6-year study.(ENDOCRINOLOGY)(bone mineral density)(Clinical report)
- Article from:
- Internal Medicine News
- Article date:
- October 15, 2009
- Author:
CopyrightCOPYRIGHT 2009 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DENVER--The investigational agent denosumab continued to increase bone mineral density in osteoporotic postmenopausal women during 6 years of continuous use, based on the results of an extension of a phase II study including 412 women.
"Over a period of 6 years, continuous treatment with denosumab resulted in progressive gains in BMD in postmenopausal women," Dr. Paul Miller said at the annual meeting of the American Society for Bone and Mineral Research.
These findings support earlier ones involving shorter follow-up of twice-yearly injections of denosumab in over 7,000 osteoporotic postmenopausal women.
The 93 patients on denosumab 60 mg for ...